

IN THE CLAIMS:

1-20. (Cancelled).

21. (Currently Amended). A method of slowing ~~treating~~ mucopolysaccharide disease progression in a patient in need thereof comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis, wherein the inhibitor of glucosylceramide synthesis is an imino sugar.

22. (Previously Presented). The method according to claim 21 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

23-24. (Canceled).

25. (Currently Amended). The method according to claim 21 ~~24~~ wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.

26. (Previously Presented). The method according to claim 25 wherein the inhibitor is N-butyldeoxynojirimycin.

27. (Canceled).

28. (Currently Amended). A method of reducing neuronal glycolipid storage in mucopolysaccharide disease in a patient in need thereof comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis, wherein the inhibitor of glucosylceramide synthesis is an imino sugar.

29. (Previously Presented). The method according to claim 28 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

30-31. (Canceled).

32. (Currently Amended). The method according to claim 28 ~~31~~ wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.

33. (Previously Presented). The method according to claim 32 wherein the inhibitor is N-butyldeoxynojirimycin.

34. (Canceled).

35. (Canceled).

36. (New). A method for reducing pathological features resulting from glycolipid accumulation in a patient with a mucopolysaccharide disease comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis, wherein the inhibitor of glucosylceramide synthesis is an imino sugar.

37. (New). A method for improving survival of a patient with a mucopolysaccharide disease comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis, wherein the inhibitor of glucosylceramide synthesis is an imino sugar.